非小细胞肺癌免疫治疗疗效与抗生素使用:系统综述与荟萃分析
该系统综述与荟萃分析纳入23项研究,评估抗生素暴露对接受免疫检查点抑制剂(ICI)治疗的非小细胞肺癌(NSCLC)患者生存的影响。荟萃分析显示,抗生素暴露与PFS(HR 1.47,95%CI 1.13-1.90)和OS(HR 1.69,95%CI 1.25-2.29)显著缩短相关,中位OS平均减少6.7个月(95%CI 5.1-8.4)。效应似乎取决于暴露时间窗,在ICI启动前后[-60天;+60天]使用抗生素影响更强。
要点
- 抗生素暴露与NSCLC患者ICI治疗后的PFS和OS显著缩短相关。
- 中位OS在抗生素暴露患者中平均减少6.7个月(95%CI 5.1-8.4)。
- ICI启动前后[-60天;+60天]使用抗生素似乎危害最大,疾病后期使用似不影响生存。
核心结论
- 在NSCLC患者中,ICI治疗前或治疗期间使用抗生素导致中位OS减少超过6个月。
- ICI启动前后短期暴露似乎特别有害,而疾病后期使用抗生素似乎不改变生存。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Cochrane图书馆和主要肿瘤学会议论文集。
- 纳入23项符合条件的研究,PFS分析纳入2208例患者,OS分析纳入5560例患者。
主要发现
- PFS的合并风险比(HR)为1.47(95%CI 1.13-1.90),OS的合并HR为1.69(95%CI 1.25-2.29)。
- PFS和OS荟萃分析的研究间异质性均较高(I2分别为69%和80%)。
- 抗生素暴露患者的中位OS平均减少6.7个月(95%CI 5.1-8.4)。
- 效应似乎取决于暴露时间窗,在ICI启动前后[-60天;+60天]使用抗生素报告效应更强。
临床怎么用
- 在NSCLC患者启动ICI治疗前后[-60天;+60天]应谨慎使用抗生素,以避免可能缩短生存。
局限性
- PFS和OS因研究间异质性高及多种混杂因素难以跨研究比较,需进一步研究加强理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors (ICIs) have dramatically improved patient outcomes in a variety of tumor types, but with variable efficacy. Recent research has suggested that antibiotic-induced disruption of the microbiota may impact ICI efficacy. We performed a systematic review and meta-analysis of studies that assessed the impact of antibiotic use on the survival of patients diagnosed with NSCLC and treated with ICI. We systematically searched Medline, the Cochrane Library, and major oncology conferences proceedings. Eligible studies mentioned hazard ratio or Kaplan-Meier curves for progression-free survival (PFS) or overall survival (OS) based on antibiotic exposure before or during ICI treatment. We identified 23 eligible studies. The impact of antibiotics was then evaluated in 2208 patients for PFS and 5560 for OS. For both PFS and OS meta-analyses, the between-study heterogeneity was high (Higgins and Thompson I2 of 69% and 80%, respectively). The pooled hazard ratio was 1.47 (95% confidence interval [CI]: 1.13-1.90) for PFS and 1.69 (95% CI: 1.25-2.29) for OS revealing a significantly reduced survival in patients with NSCLC exposed to antibiotics. The median OS was reduced on average by 6.7 months (95% CI: 5.1-8.4) in the patients exposed to antibiotics. The effect seems to depend on the time window of exposure with stronger effects reported when the patients took antibiotics [-60 days; +60 days] around ICI initiation. In patients with NSCLC, the findings of the meta-analysis indicate that antibiotic use before or during treatment with ICI leads to a median OS decreased by more than 6 months. Specifically, exposure shortly before or after ICI initiation seems to be particularly detrimental, whereas antibiotic use later during disease course does not seem to alter survival. Because PFS and OS were difficult to compare between studies owing to heterogeneity and the multiple confounding factors identified, further studies are needed to strengthen the understanding of this phenomenon.
引用
- Lurienne L, Cervesi J, Duhalde L, et al. NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2020. PMID: 32173463. doi:10.1016/j.jtho.2020.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。